Preserved Ratio Impaired Spirometry Findings and Immune Dysfunction Among Adolescents With and Without HIV in Kenya.

IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE
Chest Pub Date : 2025-03-11 DOI:10.1016/j.chest.2025.02.034
Laura E Ellington, Elizabeth Maleche-Obimbo, Brandon L Guthrie, Margaret Rosenfeld, T Eoin West, Christine J McGrath, Judith Lukorito, Christine Njiru, Anthony Cagle, Sherry Eskander, Michael H Chung, Kristina Crothers, Engi F Attia
{"title":"Preserved Ratio Impaired Spirometry Findings and Immune Dysfunction Among Adolescents With and Without HIV in Kenya.","authors":"Laura E Ellington, Elizabeth Maleche-Obimbo, Brandon L Guthrie, Margaret Rosenfeld, T Eoin West, Christine J McGrath, Judith Lukorito, Christine Njiru, Anthony Cagle, Sherry Eskander, Michael H Chung, Kristina Crothers, Engi F Attia","doi":"10.1016/j.chest.2025.02.034","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic lung disease and its association with immune dysfunction are characterized poorly among adolescents with HIV (AWHIVs).</p><p><strong>Research question: </strong>Is HIV associated with spirometry abnormalities among adolescents, and what role does immune dysfunction play?</p><p><strong>Study design and methods: </strong>We conducted a cohort study of adolescents (10-19 years of age) with and without HIV in Nairobi, Kenya. We fit adjusted log binomial models using Poisson regression to determine associations between HIV, respiratory symptoms, clinical signs, and, using exploratory factor analysis, biomarkers of immune dysregulation with spirometry abnormalities. We used linear regression to examine similar associations with continuous spirometry variables.</p><p><strong>Results: </strong>We included 154 AWHIVs (median age, 15 years [interquartile range, 13-18 years]) and 159 adolescents without HIV (AWoHs; median age, 13 years [interquartile range, 11-16 years]). Preserved ratio impaired spirometry (PRISm) findings were the predominant spirometry abnormality (20% in AWHIVs; 12% in AWoHs), followed by a restrictive spirometry pattern (RSP) (18% in AWHIVs; 12% in AWoHs) and obstructive impairments (5% in AWHIVs; 6% in AWoHs). AWHIVs showed a 1.55-fold (95% CI, 1.01-fold to 2.36-fold) increased risk of any spirometry abnormality, a 2.44-fold (95% CI, 1.40-fold to 4.26-fold) increased risk of PRISm findings, and 0.23 SD (95% CI, -0.43 to -0.03 SD) lower mean FVC z score than AWoHs. We detected no associations of respiratory symptoms or clinical signs with any spirometry abnormality among AWHIVs. AWoHs with symptoms and clinical signs were more likely to have any spirometry abnormality than AWoHs without symptoms or signs (aRR, 2.26 [95% CI, 1.23-4.17] and 2.20 [95% CI, 1.22-3.97], respectively). The biomarker factor group reflecting acute inflammation (CRP, SAA) was associated with increased risk of any spirometry abnormality among AWHIVs (aRR, 1.35 [95% CI, 1.06-1.72]) and AWoHs (1.70 [95% CI, 1.34-2.17]). Among AWHIV only, the biomarker factor grouping of endothelial activation (sCD14, soluble intercellular adhesion molecule 1, or soluble vascular cell adhesion molecule 1), lower BMI for age z score, and tobacco smoke exposure were associated with increased risk of any spirometry abnormality (aRR, 1.35 [95% CI, 1.09-1.67], 0.76 [95% CI, 0.62-0.92], and 2.34 [95% CI, 1.28-4.23], respectively) and PRISm findings.</p><p><strong>Interpretation: </strong>AWHIVs showed an increased risk of any spirometry abnormality, including PRISm findings and RSP, compared with AWoHs. Immune and endothelial activation were associated with spirometry abnormalities among AWHIVs only, suggesting alternative mechanisms of disease in AWHIVs.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2025.02.034","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic lung disease and its association with immune dysfunction are characterized poorly among adolescents with HIV (AWHIVs).

Research question: Is HIV associated with spirometry abnormalities among adolescents, and what role does immune dysfunction play?

Study design and methods: We conducted a cohort study of adolescents (10-19 years of age) with and without HIV in Nairobi, Kenya. We fit adjusted log binomial models using Poisson regression to determine associations between HIV, respiratory symptoms, clinical signs, and, using exploratory factor analysis, biomarkers of immune dysregulation with spirometry abnormalities. We used linear regression to examine similar associations with continuous spirometry variables.

Results: We included 154 AWHIVs (median age, 15 years [interquartile range, 13-18 years]) and 159 adolescents without HIV (AWoHs; median age, 13 years [interquartile range, 11-16 years]). Preserved ratio impaired spirometry (PRISm) findings were the predominant spirometry abnormality (20% in AWHIVs; 12% in AWoHs), followed by a restrictive spirometry pattern (RSP) (18% in AWHIVs; 12% in AWoHs) and obstructive impairments (5% in AWHIVs; 6% in AWoHs). AWHIVs showed a 1.55-fold (95% CI, 1.01-fold to 2.36-fold) increased risk of any spirometry abnormality, a 2.44-fold (95% CI, 1.40-fold to 4.26-fold) increased risk of PRISm findings, and 0.23 SD (95% CI, -0.43 to -0.03 SD) lower mean FVC z score than AWoHs. We detected no associations of respiratory symptoms or clinical signs with any spirometry abnormality among AWHIVs. AWoHs with symptoms and clinical signs were more likely to have any spirometry abnormality than AWoHs without symptoms or signs (aRR, 2.26 [95% CI, 1.23-4.17] and 2.20 [95% CI, 1.22-3.97], respectively). The biomarker factor group reflecting acute inflammation (CRP, SAA) was associated with increased risk of any spirometry abnormality among AWHIVs (aRR, 1.35 [95% CI, 1.06-1.72]) and AWoHs (1.70 [95% CI, 1.34-2.17]). Among AWHIV only, the biomarker factor grouping of endothelial activation (sCD14, soluble intercellular adhesion molecule 1, or soluble vascular cell adhesion molecule 1), lower BMI for age z score, and tobacco smoke exposure were associated with increased risk of any spirometry abnormality (aRR, 1.35 [95% CI, 1.09-1.67], 0.76 [95% CI, 0.62-0.92], and 2.34 [95% CI, 1.28-4.23], respectively) and PRISm findings.

Interpretation: AWHIVs showed an increased risk of any spirometry abnormality, including PRISm findings and RSP, compared with AWoHs. Immune and endothelial activation were associated with spirometry abnormalities among AWHIVs only, suggesting alternative mechanisms of disease in AWHIVs.

PRISm与肯尼亚感染和未感染艾滋病毒的青少年的免疫功能障碍。
背景:慢性肺部疾病及其与免疫功能障碍的关联在青少年HIV (AWHIV)中尚不清楚。研究问题:艾滋病毒是否与青少年肺活量异常有关?免疫功能障碍在其中扮演什么角色?研究设计和方法:我们对肯尼亚内罗毕感染和未感染艾滋病毒的青少年(10-19岁)进行了一项队列研究。我们使用泊松回归拟合调整后的对数二项模型,以确定HIV、呼吸道症状、临床体征之间的关系,并使用探索性因素分析,确定免疫失调的生物标志物与肺活量异常之间的关系。我们使用线性回归来检验与连续肺活量测量变量的类似关联。结果:我们纳入154例awhv(中位年龄15岁[Q1,Q3:13,18])和159例无HIV (AWoH)(13岁[Q1,Q3:11,16])。保留比例肺功能受损(PRISm)是主要的肺功能异常(20% AWHIV;12% AWoH),其次是限制性肺活量测定模式(RSP) (18% AWHIV;12% AWoH)和梗阻性损伤(5% AWHIV;AWoH 6%)。与AWoH相比,AWHIV的肺活量异常风险增加1.55倍(95%CI 1.01-2.36), PRISm风险增加2.44倍(1.40-4.26),平均FVC z-score降低0.23 (-0.43- -0.03)SD。我们未发现awhv患者的呼吸症状或临床体征与任何肺活量测定异常相关。有症状和临床体征的AWoH比无症状/体征的AWoH更容易出现肺功能异常(aRR分别为2.26[95%CI 1.23-4.17]和2.20[1.22-3.97])。反映急性炎症的生物标志物因子组(CRP, SAA)与AWHIV (aRR 1.35[95%CI 1.06-1.72])和AWoH(1.70[1.34-2.17])中任何肺活量测量异常的风险增加相关。仅在AWHIV中,内皮细胞活化(sCD14、sICAM-1、sVCAM-1)、较低的年龄bmi z-score和烟草烟雾暴露与任何肺活量测量异常的风险增加相关(aRR分别为1.35[95%CI 1.09-1.67]、0.76[0.62-0.92]、2.34[1.28-4.23])和PRISm。解释:与AWoH相比,AWHIV增加了任何肺活量异常的风险,包括PRISm和RSP。仅在AWHIV中,免疫和内皮细胞激活与肺活量异常相关,提示AWHIV的其他疾病机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chest
Chest 医学-呼吸系统
CiteScore
13.70
自引率
3.10%
发文量
3369
审稿时长
15 days
期刊介绍: At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信